We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer (STELA)

This study is currently recruiting participants.
Verified September 2016 by Jenny C. Chang, MD, The Methodist Hospital System
Sponsor:
ClinicalTrials.gov Identifier:
NCT02073916
First Posted: February 27, 2014
Last Update Posted: September 14, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
The Methodist Hospital System
Information provided by (Responsible Party):
Jenny C. Chang, MD, The Methodist Hospital System
  Purpose

This open-label, single-center study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) to Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer. Patients will receive Abraxane on Day 1 of each 1-week cycle and T-DM1 on Day 1 of each 3-week cycle. Patients with take Lapatinib orally daily. Anticipated time on study treatment is up to 12 weeks for patients metastatic breast cancer, until disease progression or unacceptable toxicity occurs. Subjects may continue on treatment past 12 weeks if responding to study treatment.

The purpose of this study is to test the safety of Trastuzumab Emtansine in combination with Abraxane and Lapatinib at different dose levels. The investigators are proposing in this phase Ib study to assess the maximum tolerated dose (MTD) of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane in metastatic Her2 over-expressed breast cancer.

The investigators hypothesize that combining antibody-drug conjugate trastuzumab-emtansine and lapatinib together with Abraxane will improve clinical efficacy by affecting both PI3K and ERK1,2 MAPK pathways.


Condition Intervention Phase
Metastatic Breast Cancer Drug: TDM1 Drug: Lapatinib Drug: Abraxane Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients

Resource links provided by NLM:


Further study details as provided by Jenny C. Chang, MD, The Methodist Hospital System:

Primary Outcome Measures:
  • Maximum Tolerable Dose [ Time Frame: approximately 16 weeks ]
    Maximum tolerated dose (MTD) of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane in metastatic Her2 over-expressed breast cancer.


Secondary Outcome Measures:
  • Dose Limiting Toxicities [ Time Frame: From date of randomization through study follow up (approximately 16 weeks) ]
    Describe the dose-limiting toxicity (DLT) associated with Trastuzumab Emtansine in combination with Lapatinib plus Abraxane as assessed by CTCAE v4.0.

  • Measure toxicities associated with treatment combination [ Time Frame: From date of randomization through study follow up (approximately 16 weeks) ]
    Describe and measure other toxicities associated with Trastuzumab Emtansine in combination with Lapatinib plus Abraxane as assessed by CTCAE v4.0.

  • Anti-tumor activity through imaging [ Time Frame: approximately 16 weeks from randomization ]
    Document anti-tumor activity of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane in metastatic Her2 over-expressed breast cancer as assessed by RECIST 1:1 criteria

  • Plasma pharmacokinetics and pharmacodynamic effect of treatment combination [ Time Frame: Day 1 and 1,2,4,and 24hours ]
    Determine the plasma pharmacokinetics of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane.


Estimated Enrollment: 45
Study Start Date: October 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TDM1 with Lapatinib followed by Abraxane
TDM1 with Laptinib followed by Abraxane
Drug: TDM1
•Drug: abraxane Intravenous repeating dose weekly
Other Names:
  • Trastuzumab Emtansine
  • TDM-1
  • TE
  • Kadcyla
Drug: Lapatinib
Oral repeating dose daily
Other Name: Tykerb
Drug: Abraxane
Intravenous repeating dose weekly

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented metastatic Her2 over-expressed breast cancer.
  • Age ≥ 18 years Patients must have received at least two prior therapies for their malignant disease.
  • Patients must have < Grade 2 pre-existing peripheral neuropathy (per CTCAE)
  • Adequate organ function (cardiac ejection fraction of ≥ 45%),
  • CBC not less than .75 of institutional lower limit.
  • Patients must have adequate liver function: AST and ALT < 2.5 X upper limit of normal, alkaline phosphatase < 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis Bilirubin < 1.5 mg/dL
  • Patients must have adequate renal function: creatinine <1.5 mg/dL is recommended; however, institutional norms are acceptable.
  • Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential
  • Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed). Contraception method must be used during treatment and for three months after completing treatment Signed informed consent form (ICF)

Exclusion Criteria:

  • Any medical or psychiatric condition that would prevent informed consent or limit survival to less than 4 weeks.
  • Absolute QT interval of >460 msec in the presence of potassium >4.0mEq/L and Magnesium >1.8mg/dl.
  • Patient with HIV and post- transplant associated lymphoproliferative disorders.
  • Patient with concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of Trastuzumab Emtansine, Lapatinib or Abraxane.
  • Pregnant or lactating women.
  • Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine, lapatinib, abraxane, or their components.
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
  • Subjects with ulcerative colitis are also excluded.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02073916


Contacts
Contact: Houston Methodist Cancer Center 713-441-0629 ccresearch@houstonmethodist.org

Locations
United States, Texas
Houston Methodist Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Cancer Center    713-441-0629    ccresearch@houstonmethodist.org   
Principal Investigator: Jenny CN Chang, MD         
Sub-Investigator: Angel A Rodriguez, MD         
Sub-Investigator: Tejal Patel, MD         
Sub-Investigator: Daniel Lehane, MD         
Sub-Investigator: Monisha Singh, MD         
Sub-Investigator: Jorge Darcourt, MD         
Sponsors and Collaborators
Jenny C. Chang, MD
The Methodist Hospital System
Investigators
Principal Investigator: Jenny C Chang, MD The Methodist Hospital System
  More Information

Additional Information:
Responsible Party: Jenny C. Chang, MD, Sponsor-Investigator/Principal Investigator, The Methodist Hospital System
ClinicalTrials.gov Identifier: NCT02073916     History of Changes
Other Study ID Numbers: 0813-0139
First Submitted: February 18, 2014
First Posted: February 27, 2014
Last Update Posted: September 14, 2016
Last Verified: September 2016

Keywords provided by Jenny C. Chang, MD, The Methodist Hospital System:
Breast Cancer
HER2 positive Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Lapatinib
Ado-trastuzumab emtansine
Trastuzumab
Albumin-Bound Paclitaxel
Paclitaxel
Maytansine
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators